Active, not recruitingPhase 2NCT05406674

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer

Studying OBSOLETE: Primary peritoneal serous/papillary carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Netherlands Cancer Institute
Principal Investigator
W. van Driel, MD PhD
NKI-AvL
Intervention
Cisplatin 100 mg/m2(drug)
Enrollment
40 enrolled
Eligibility
18 years · FEMALE
Timeline
20222027

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05406674 on ClinicalTrials.gov

Other trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma

← Back to all trials